FDA Gives Fast-Track Status to Anadys’ Hepatitis C Drug Candidate

Bruce V. Bigelow12/3/08

Shares of San Diego’s Anadys Pharmaceuticals (NASDAQ: ANDS) gave up some of the boost they got Tuesday after the company announced the Food and Drug Administration put the biotech’s drug candidate for hepatitis C on fast-track review. Anadys shares fell in early trading today, after gaining almost 20 percent Tuesday. Shares have traded between $1.36 and $3.13 over the past year. The FDA’s fast-track status is usually used for prospective drugs intended to treat serious and life-threatening diseases that lack current treatments.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788